Efficacy and safety of Mahuang Fuzi and Shenzhuo Decoction for treatment of primary membranous nephropathy: a multicenter prospective trial

References

• Xu X, Wang G, Chen N, et al. Long-term exposure to air pollution and increased risk of membranous nephropathy in China. J Am Soc Nephrol. 2016;27(12):1–11. doi: 10.1681/ASN.2016010093.
   PubMed Web of Science ®Google Scholar
• Qian Q, Nasr SH. Diagnosis and treatment of glomerular diseases in elderly patients. Adv Chronic Kidney Dis. 2014;21(2):228–246. doi: 10.1053/j.ackd.2014.01.004.
   PubMed Web of Science ®Google Scholar
• Couser WG. Primary membranous nephropathy. Clin J Am Soc Nephrol. 2017;12(6):983–997. doi: 10.2215/CJN.11761116.
   PubMed Web of Science ®Google Scholar
• Beck LHJr., Bonegio RG, Lambeau G, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med. 2009;361(1):11–21. doi: 10.1056/NEJMoa0810457.
   PubMed Web of Science ®Google Scholar
• Meyer-Schwesinger C, Lambeau G, Stahl RA. Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. N Engl J Med. 2015;372(11):1074–1075. doi: 10.1056/NEJMc1500130.
   PubMed Web of Science ®Google Scholar
• Liu W, Huang G, Rui H, et al. Course monitoring of membranous nephropathy: both autoantibodies and podocytes require multidimensional attention. Autoimmun Rev. 2022;21(2):102976. doi: 10.1016/j.autrev.2021.102976.
   PubMed Web of Science ®Google Scholar
• Cattran DC. Membranous nephropathy: quo vadis? Kidney Int. 2002;61(1):349–350. doi: 10.1046/j.1523-1755.2002.00125.x.
   PubMed Web of Science ®Google Scholar
• Rovin BH, Adler SG, Barratt J, et al. Executive summary of the KDIGO 2021 guideline for the management of glomerular diseases. Kidney Int. 2021;100(4):753–779. doi: 10.1016/j.kint.2021.05.015.
   PubMed Web of Science ®Google Scholar
• Dahan K, Debiec H, Plaisier E, et al. Rituximab for severe membranous nephropathy: a 6-month trial with extended follow-up. J Am Soc Nephrol. 2017;28(1):348–358. doi: 10.1681/ASN.2016040449.
   PubMed Web of Science ®Google Scholar
• Howman A, Chapman TL, Langdon MM, et al. Immunosuppression for progressive membranous nephropathy: a UK randomised controlled trial. Lancet. 2013;381(9868):744–751. doi: 10.1016/S0140-6736(12)61566-9.
   PubMed Web of Science ®Google Scholar
• Wang J, Xie Q, Sun Z, et al. Response to immunosuppressive therapy in PLA(2)R-associated and non-PLA(2)R- associated idiopathic membranous nephropathy: a retrospective, multicenter cohort study. BMC Nephrol. 2017;18(1):227. doi: 10.1186/s12882-017-0636-0.
   PubMedGoogle Scholar
• Seitz-Polski B, Dahan K, Debiec H, et al. High-dose rituximab and early remission in PLA2R1-related membranous nephropathy. Clin J Am Soc Nephrol. 2019;14(8):1173–1182. doi: 10.2215/CJN.11791018.
   PubMed Web of Science ®Google Scholar
• Praga M, Barrio V, Juárez GF, et al. Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trial. Kidney Int. 2007;71(9):924–930. doi: 10.1038/sj.ki.5002215.
   PubMed Web of Science ®Google Scholar
• Fervenza FC, Appel GB, Barbour SJ, et al. Rituximab or cyclosporine in the treatment of membranous nephropathy. N Engl J Med. 2019;381(1):36–46. doi: 10.1056/NEJMoa1814427.
   PubMed Web of Science ®Google Scholar
• Fernández-Juárez G, Rojas-Rivera J, Logt AV, et al. The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy. Kidney Int. 2021;99(4):986–998. doi: 10.1016/j.kint.2020.10.014.
   PubMed Web of Science ®Google Scholar
• Scolari F, Delbarba E, Santoro D, et al. Rituximab or cyclophosphamide in the treatment of membranous nephropathy: the RI-CYCLO randomized trial. J Am Soc Nephrol. 2021;32(4):972–982. doi: 10.1681/ASN.2020071091.
   PubMed Web of Science ®Google Scholar
• Lu Z, Liu W, Gao H, et al. Traditional Chinese medicine as an adjunct therapy in the treatment of idiopathic membranous nephropathy: a systematic review and meta-analysis. PLOS One. 2021;16(5):e0251131. doi: 10.1371/journal.pone.0251131.
   PubMed Web of Science ®Google Scholar
• Chen Y, Deng Y, Ni Z, et al. Efficacy and safety of traditional Chinese medicine (Shenqi particle) for patients with idiopathic membranous nephropathy: a multicenter randomized controlled clinical trial. Am J Kidney Dis. 2013;62(6):1068–1076. doi: 10.1053/j.ajkd.2013.05.005.
   PubMed Web of Science ®Google Scholar
• Shi B, Zhang RR, Liang Y, et al. Efficacy of traditional Chinese medicine regimen Jian Pi Qu Shi formula for refractory patients with idiopathic membranous ­nephropathy: a retrospective case-series study. Evid Based Complement Alternat Med. 2018;2018:5854710. doi: 10.1155/2018/5854710.
   PubMed Web of Science ®Google Scholar
• Dong Z, Dai H, Gao Y, et al. Effect of Mahuang Fuzi and Shenzhuo Decoction on idiopathic membranous nephropathy: a multicenter, nonrandomized, single-arm clinical trial. Front Pharmacol. 2021;12:724744. doi: 10.3389/fphar.2021.724744.
   PubMed Web of Science ®Google Scholar
• Chapter 2: general principles in the management of glomerular disease. Kidney Int Suppl. 2012;2(2):156–162.
   Google Scholar
• Chapter 7: idiopathic membranous nephropathy. Kidney Int Suppl. 2012;2(2):186–197.
   Web of Science ®Google Scholar
• Kim Y, Yoon HE, Chung BH, et al. Clinical outcomes and effects of treatment in older patients with idiopathic membranous nephropathy. Korean J Intern Med. 2019;34(5):1091–1099. doi: 10.3904/kjim.2018.139.
   PubMed Web of Science ®Google Scholar
• Bae E, Lee SW, Park S, et al. Treatment and clinical outcomes of elderly idiopathic membranous nephropathy: a multicenter cohort study in Korea. Arch Gerontol Geriatr. 2018;76:175–181. doi: 10.1016/j.archger.2018.03.002.
   PubMed Web of Science ®Google Scholar
• Xiaofan H, Jing X, Chenni G, et al. New risk score for predicting progression of membranous nephropathy. J Transl Med. 2019;17(1):41. doi: 10.1186/s12967-019-1792-8.
   PubMedGoogle Scholar
• He P, Zha Y, Liu J, et al. Clinical outcomes of patients with primary membranous nephropathy and subnephrotic proteinuria. Front Med. 2021;8:737700. doi: 10.3389/fmed.2021.737700.
   Web of Science ®Google Scholar
• Jurubiță R, Obrișcă B, Sorohan B, et al. Clinical phenotypes and predictors of remission in primary membranous nephropathy. J Clin Med. 2021;10(12):2624. doi: 10.3390/jcm10122624.
   PubMed Web of Science ®Google Scholar
• Gao Y, Dai H, Zhang N, et al. The ameliorative effect of Mahuang Fuzi and Shenzhuo Decoction on membranous nephropathy of rodent model is associated with autophagy and Wnt/β-catenin pathway. Front Pharmacol. 2022;13:820130. doi: 10.3389/fphar.2022.820130.
   PubMed Web of Science ®Google Scholar
• Zhang N, Dai H, Dong X, et al. Level of interleukin-35 in patients with idiopathic membranous nephropathy and its predictive value for remission time. Front Immunol. 2022;13:926368. doi: 10.3389/fimmu.2022.926368.
   PubMed Web of Science ®Google Scholar